Skip to main content
Article thumbnail
Location of Repository

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

By Alessandra Fabi, Giulio Metro, Michelangelo Russillo, Antonello Vidiri, Carmine Maria Carapella, Marta Maschio, Francesco Cognetti, Bruno Jandolo, Maria Alessandra Mirri, Isabella Sperduti, Stefano Telera, Mariantonia Carosi and Andrea Pace
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2008). Biti G: Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs
  2. (2008). Boiardi A: Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
  3. (1990). Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma.
  4. (2008). Cancer: principles & practice of oncology 8th edition.
  5. (2002). Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet
  6. (1991). Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies. Chemotherapy
  7. (2004). Ermani M: Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
  8. (2004). Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene
  9. (1988). Guaitani A: Antitumor activity of the novel nitrosourea S10036 in rodent tumors. Anticancer Res
  10. (2001). Heimans JJ: PCV chemotherapy for recurrent glioblastoma multiforme. Neurology
  11. (2004). Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J Pharmacol Exp Ther
  12. (1999). JP: Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas. Bull Cancer
  13. (2008). Kesari S: Malignant gliomas in adults.
  14. (2008). KL: Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
  15. (2004). L: BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
  16. (2003). Marosi C: Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. Anticancer Drugs
  17. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma.
  18. (2005). Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
  19. (1991). Phase II study of fotemustine in recurrent supratentorial malignant gliomas.
  20. (1997). Prakash AS: Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity. Biochemistry
  21. (1972). Regression models and life tables.
  22. (1980). Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. Med Chem
  23. (2008). Safety and efficacy of fotemustine in recurrent or progressive gliomas [abstract].
  24. (2008). Solero CL, Valsecchi MG: Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol
  25. Terminology Criteria for Adverse Events v3.0 (CTCAE)
  26. (2007). WP: MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst)

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.